Onco-dermatology : collaboration between Redx Pharma and Pierre Fabre
February 27th, 2014 Redx Pharma and Pierre Fabre Laboratories have today completed a collaboration and option agreement in cancer research.
The exclusive deal will see Redx and Pierre Fabre Research Institute (IRPF) work together on the evaluation and development of a small molecule program for an undisclosed oncology target. Following the first stage of the collaboration, IRPF will have the option to enter into exclusive negotiations to license global rights for the program in selected cancer indications.
The Redx Pharma group is focused on early stage drug discovery and development programmes and provides translational research capacity and expertise with a focus in areas such as cancer stem cells, tumour immunology and anti-microbial resistance.
Neil Murray, chief executive, Redx Pharma said: “We are delighted to have reached an agreement with Pierre Fabre, which represents the first major transaction for our anti-cancer subsidiary Redx Oncology. The collaboration demonstrates the potential of our oncology pipeline to deliver novel cancer therapeutics which all concerned hope will generate significant patient benefits. We look forward to benefitting from Pierre Fabre’s outstanding capabilities in this area and look forward to a long and successful partnership.”
Christian Bailly, Head of Research at Pierre Fabre Pharmaceuticals, said: “We are looking forward to working with Redx Pharma as part of our commitment to external innovation to complete our cutting-edge R&D capabilities. This collaboration with Redx Oncology, a dynamic and visionary biotech company, marks an additional milestone in our partnering research strategy. Combining our capabilities with Redx researchers will accelerate our drug discovery process.”